LEXICON PHARMACEUTICALS, INC. Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer of $25.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Income Statement › Other Income
us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer · last filed 2025-03-07
- LEXICON PHARMACEUTICALS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2024 was $25.00M.
- LEXICON PHARMACEUTICALS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2023 was $0.00.
- LEXICON PHARMACEUTICALS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2022 was $0.00.
| Period end | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 12 month |
|---|---|
| 2024-12-31 | $25.00M 10-K · filed 2025-03-07 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-07 |
| 2022-12-31 | $0.00 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |